rs2120019 — PPCDC

PPCDC rs2120019 — A Genetic Driver of Serum Zinc Variation

Your serum zinc level is not set only by diet. A common variant in the PPCDC gene¹¹ PPCDC gene
Phosphopantothenoylcysteine decarboxylase, an enzyme that catalyses the fifth step of coenzyme A biosynthesis from pantothenic acid (vitamin B5) influences how much zinc circulates in your blood, independently of how much you consume. Carriers of the C allele at rs2120019 tend to have lower serum zinc on average, an effect large enough to be genome-wide significant and consistently replicated as a genetic instrument in Mendelian randomization studies of zinc's role in cardiometabolic and infectious disease.

The Mechanism

PPCDC is not itself a zinc transporter. It encodes an enzyme in the coenzyme A (CoA) biosynthesis pathway²² coenzyme A (CoA) biosynthesis pathway
CoA is an essential cofactor in more than 100 enzymatic reactions including fatty acid synthesis, the citric acid cycle, and amino acid catabolism — converting 4'-phosphopantothenoylcysteine to 4'-phosphopantetheine. The intronic rs2120019 variant does not alter the PPCDC protein directly. Instead, the proposed mechanism is indirect: PPCDC variation may affect pantothenate metabolite pools, which in turn influence the expression or activity of downstream zinc homeostasis proteins, including zinc transporters expressed in the intestine and liver.

This mechanistic link remains incompletely characterized — the original GWAS authors acknowledged that "other genetic variation in the CoA synthesis pathway, specifically in PPCDC, could also lead to variation in Zn metabolism," while cautioning that this "cannot be taken further with current data." The association is robust at the epidemiological level (genome-wide significant, replicated across cohorts) even while the precise biochemical pathway is still under investigation.

The Evidence

The primary evidence comes from a genome-wide association study in 5,477 adults³³ genome-wide association study in 5,477 adults
Evans DM et al. Genome-wide association study identifies loci affecting blood copper, selenium and zinc. Hum Mol Genet, 2013 from the QIMR cohort (Australian twins and families) and the ALSPAC cohort (UK pregnant women). The rs2120019 C allele was associated with lower blood zinc at P = 1.55 × 10⁻¹⁸ (β = −0.287, SE = 0.033 standard deviations per C allele). This locus on chromosome 15 was one of only three genome-wide significant zinc signals identified, alongside chromosome 8 (near carbonic anhydrase genes) and chromosome X.

rs2120019 has subsequently been used as a standard genetic instrument in multiple Mendelian randomization studies. A 2018 two-sample MR study⁴⁴ 2018 two-sample MR study
Thun GA et al. Effects of copper and zinc on ischemic heart disease and myocardial infarction: a Mendelian randomization study. Am J Clin Nutr, 2018 found that the zinc instruments (including rs2120019) together explained ≥8% of variance in erythrocyte zinc and showed genetically instrumented higher zinc was associated with a modest increase in ischemic heart disease risk (OR 1.06; 95% CI 1.02–1.11). This counterintuitive finding — often interpreted as reflecting the U-shaped nature of zinc biology, where both deficiency and excess can be harmful — underscores that simply supplementing zinc indiscriminately is not appropriate even for lower-zinc genotypes.

In COVID-19 research, Moghaddam et al. 2021⁵⁵ Moghaddam et al. 2021
Association of Vitamin D, Zinc and Selenium Related Genetic Variants With COVID-19 Disease Severity. Front Nutr, 2021 included rs2120019 as the representative zinc genetic marker, while a larger MR analysis (Li et al. 2022⁶⁶ Li et al. 2022
Genetically Predicted Circulating Concentrations of Micronutrients and COVID-19 Susceptibility and Severity. Front Nutr, 2022) found limited evidence that genetically predicted zinc levels causally affect COVID-19 outcomes (OR 1.06 for hospitalization, 95% CI 0.81–1.39, p=0.66).

Practical Actions

The C allele at rs2120019 nudges serum zinc downward by roughly a quarter to a third of a standard deviation per copy. For a CC homozygote, this represents a meaningful shift in baseline zinc status that is worth accounting for in diet and monitoring — but does not require aggressive supplementation. Zinc is measured in serum or plasma; levels below 70 µg/dL in adults suggest inadequacy.

The best dietary sources of bioavailable zinc are shellfish (especially oysters), red meat, poultry, and legumes. Phytates in whole grains and legumes reduce zinc absorption, so soaking, sprouting, or fermenting these foods improves bioavailability. Supplemental zinc citrate and zinc gluconate are both absorbed at approximately 60%; zinc oxide has lower absorption at around 50%.

Avoid supplementing beyond 25 mg elemental zinc daily without confirmed deficiency — excess zinc can deplete copper, impair immune function, and, based on Mendelian randomization data, may be associated with elevated cardiovascular risk at the higher end of the zinc distribution.

Interactions

rs2120019 is one of three established zinc GWAS loci. The other two — rs1532423 (chromosome 8, near carbonic anhydrase genes) and rs11638477 (also associated with zinc) — are independent signals with separate mechanisms. Carrying the zinc-lowering allele at more than one of these loci would compound the downward shift in baseline zinc status, increasing the relevance of dietary zinc optimization and periodic monitoring.

Zinc bioavailability interacts with dietary copper: high-zinc supplementation competes with copper absorption, and vice versa. Users with both zinc-lowering and copper-altering variants should assess both minerals together rather than supplementing either in isolation.